Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors.

[1]  T. Wieland,et al.  G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity , 2005 .

[2]  G. Piñeyro,et al.  Internalization and Src Activity Regulate the Time Course of ERK Activation by Delta Opioid Receptor Ligands* , 2005, Journal of Biological Chemistry.

[3]  R. Lefkowitz,et al.  Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Lefkowitz,et al.  Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Willem Soudijn,et al.  Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. , 2004, Drug discovery today.

[6]  R. Lefkowitz.  Historical review: a brief history and personal retrospective of seven-transmembrane receptors. , 2004, Trends in pharmacological sciences.

[7]  Terry Kenakin,et al.  Allosteric modulators: the new generation of receptor antagonist. , 2004, Molecular interventions.

[8]  S. Kudoh,et al.  Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II , 2004, Nature Cell Biology.

[9]  T. Kenakin.  Principles: receptor theory in pharmacology. , 2004, Trends in pharmacological sciences.

[10]  T. Schwartz,et al.  Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. , 2004, Trends in pharmacological sciences.

[11]  R. Leurs,et al.  Constitutively active Gq/11-coupled Receptors Enable Signaling by Co-expressed Gi/o-coupled Receptors* , 2004, Journal of Biological Chemistry.

[12]  T. Kenakin.  Efficacy as a vector: the relative prevalence and paucity of inverse agonism. , 2004, Molecular pharmacology.

[13]  Francine Acher,et al.  Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[15]  G. Milligan.  Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. , 2003, Molecular pharmacology.

[16]  Pascale G. Charest,et al.  β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Shayo,et al.  Tiotidine, a histamine H2 receptor inverse agonist that binds with high affinity to an inactive G-protein-coupled form of the receptor. Experimental support for the cubic ternary complex model. , 2003, Molecular pharmacology.

[18]  R. Leurs,et al.  Virally encoded G protein-coupled receptors: targets for potentially innovative anti-viral drug development. , 2003, Current drug targets.

[19]  M. Kas,et al.  Inverse agonism gains weight. , 2003, Trends in pharmacological sciences.

[20]  J. Kew,et al.  Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.

[21]  P. Corvol,et al.  Lessons from constitutively active mutants of G protein-coupled receptors , 2002, Trends in Endocrinology & Metabolism.

[22]  R. Seifert,et al.  Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[23]  L. Prézeau,et al.  A model for the functioning of family 3 GPCRs. , 2002, Trends in pharmacological sciences.

[24]  U. Hacksell,et al.  Discovery of an ectopic activation site on the M(1) muscarinic receptor. , 2002, Molecular pharmacology.

[25]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[26]  Francesca Fanelli,et al.  Mutagenesis and modelling of the alpha(1b)-adrenergic receptor highlight the role of the helix 3/helix 6 interface in receptor activation. , 2002, Molecular pharmacology.

[27]  P. Strange.  Mechanisms of inverse agonism at G-protein-coupled receptors. , 2002, Trends in pharmacological sciences.

[28]  A. Scheer,et al.  Mutational and computational analysis of the alpha(1b)-adrenergic receptor. Involvement of basic and hydrophobic residues in receptor activation and G protein coupling. , 2001, The Journal of biological chemistry.

[29]  M. Bianchi,et al.  Agonist Trapping by GABAA Receptor Channels , 2001, The Journal of Neuroscience.

[30]  W. Spooren,et al.  Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. , 2001, Trends in pharmacological sciences.

[31]  T. Schwartz,et al.  Virally encoded 7TM receptors , 2001, Oncogene.

[32]  R. Adan,et al.  AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. , 2001, Molecular endocrinology.

[33]  Holger Stark,et al.  High constitutive activity of native H3 receptors regulates histamine neurons in brain , 2000, Nature.

[34]  T. Costa,et al.  Intramolecular Dynamics and Ligand-Induced Conformational Changes: A Stochastic Model of Receptor Action , 2000 .

[35]  A. IJzerman,et al.  Inverse agonism at G protein‐coupled receptors: (patho)physiological relevance and implications for drug discovery , 2000, British journal of pharmacology.

[36]  A. Scheer,et al.  A Look at Receptor Efficacy. From the Signalling Network of the Cell to the Intramolecular Motion of the Receptor , 2000 .

[37]  Arthur Christopoulos.  Biomedical Applications of Computer Modeling , 2000 .

[38]  J. Way,et al.  Constitutive receptor systems for drug discovery. , 1999, Journal of pharmacological and toxicological methods.

[39]  A. Gobert,et al.  Inverse Agonists and Serotonergic Transmission: From Recombinant, Human Serotonin (5-HT)1B Receptors to G-Protein Coupling and Function in Corticolimbic Structures in vivo , 1999, Neuropsychopharmacology.

[40]  P Ghanouni,et al.  Mutation of a highly conserved aspartic acid in the beta2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. , 1999, Molecular pharmacology.

[41]  R. Leurs,et al.  Agonist-independent regulation of constitutively active G-protein-coupled receptors. , 1998, Trends in biochemical sciences.

[42]  D. Colquhoun,et al.  Binding, gating, affinity and efficacy: The interpretation of structure‐activity relationships for agonists and of the effects of mutating receptors , 1998, British journal of pharmacology.

[43]  Robert J. Lefkowitz,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[44]  E A Barnard,et al.  International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. , 1998, Pharmacological reviews.

[45]  E. Cera.  Site-Specific Thermodynamics: Understanding Cooperativity in Molecular Recognition. , 1998 .

[46]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[47]  B. Lanske,et al.  Targeted expression of constitutively active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescues mice that lack parathyroid hormone-related peptide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  H Weinstein,et al.  Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor , 1997, The EMBO journal.

[49]  E. Sigel,et al.  The benzodiazepine binding site of GABAA receptors. , 1997, Trends in pharmacological sciences.

[50]  G. Barsh,et al.  Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. , 1997, Science.

[51]  P. Casellas,et al.  A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1 , 1997, The Journal of Biological Chemistry.

[52]  G. Liapakis,et al.  Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment* , 1997, The Journal of Biological Chemistry.

[53]  A. Scheer,et al.  The activation process of the alpha1B-adrenergic receptor: potential role of protonation and hydrophobicity of a highly conserved aspartate. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Brian K. Kobilka,et al.  Structural Instability of a Constitutively Active G Protein-coupled Receptor , 1997, The Journal of Biological Chemistry.

[55]  J. Steinbach,et al.  Bicuculline and Gabazine Are Allosteric Inhibitors of Channel Opening of the GABAA Receptor , 1997, The Journal of Neuroscience.

[56]  R. Cone,et al.  Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice , 1997, Cell.

[57]  T. Kenakin,et al.  The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy. , 1996, Journal of theoretical biology.

[58]  A. Scheer,et al.  Constitutively active mutants of the alpha 1B‐adrenergic receptor: role of highly conserved polar amino acids in receptor activation. , 1996, The EMBO journal.

[59]  J. Proska,et al.  Allosteric modulation of muscarinic acetylcholine receptors. , 1995, Trends in pharmacological sciences.

[60]  M. Birnbaumer,et al.  Mutations and diseases of G protein coupled receptors. , 1995, Journal of receptor and signal transduction research.

[61]  R. Lefkowitz,et al.  Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[62]  K. Jakobs,et al.  Unoccupied beta-adrenoceptor-induced adenylyl cyclase stimulation in turkey erythrocyte membranes. , 1994, European journal of pharmacology.

[63]  R. Twyman,et al.  Benzodiazepine and beta‐carboline regulation of single GABAA receptor channels of mouse spinal neurones in culture. , 1994, The Journal of physiology.

[64]  R. Olsen,et al.  GABAA receptor channels. , 1994, Annual review of neuroscience.

[65]  T. Minegishi,et al.  A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty , 1993, Nature.

[66]  J. Parma,et al.  Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas , 1993, Nature.

[67]  R. Lefkowitz,et al.  Constitutively active mutants of the alpha 2-adrenergic receptor. , 1993, The Journal of biological chemistry.

[68]  R. Lefkowitz,et al.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.

[69]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[70]  Y. Li,et al.  Agonist‐independent effects of muscarinic antagonists on Ca2+ and K+ currents in frog and rat cardiac cells. , 1993, The Journal of physiology.

[71]  K. Jakobs,et al.  Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes. , 1992, European journal of pharmacology.

[72]  D Rodbard,et al.  Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. , 1992, Molecular pharmacology.

[73]  M. Caron,et al.  Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. , 1992, The Journal of biological chemistry.

[74]  W. Schütz,et al.  Reverse intrinsic activity of antagonists on G protein-coupled receptors. , 1992, Trends in pharmacological sciences.

[75]  M. Caron,et al.  G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[76]  M. Caron,et al.  Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[77]  A. Herz,et al.  Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. , 1990, Molecular pharmacology.

[78]  J. Wyman,et al.  Binding and Linkage: Functional Chemistry of Biological Macromolecules , 1990 .

[79]  A Herz,et al.  Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[80]  E. Ross,et al.  Functional activation of beta-adrenergic receptors by thiols in the presence or absence of agonists. , 1985, The Journal of biological chemistry.

[81]  M. Caron,et al.  The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. , 1984, Biochemistry.

[82]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[83]  C. Braestrup,et al.  Interaction of convulsive ligands with benzodiazepine receptors. , 1982, Science.

[84]  R. Lefkowitz,et al.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.

[85]  C. Olsen,et al.  Urinary and brain beta-carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[86]  R. Lefkowitz,et al.  A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. , 1980, Molecular pharmacology.

[87]  G. Weber,et al.  Energetics of ligand binding to proteins. , 1975, Advances in protein chemistry.

[88]  L. Birnbaumer,et al.  The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. IV. Effects of guanylnucleotides on binding of 125I-glucagon. , 1971, The Journal of biological chemistry.

[89]  Bernard,et al.  Advances in Drug Research , 1964 .

[90]  Bernard Katz,et al.  Interaction at end-plate receptors between different choline derivatives , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[91]  R P STEPHENSON,et al.  A MODIFICATION OF RECEPTOR THEORY , 1997, British journal of pharmacology and chemotherapy.